Cargando…

A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth

BACKGROUND: Immune checkpoint blocker (ICB) therapy has shown survival benefits for some patients with cancer. Nevertheless, many individuals remain refractory or acquire resistance to treatment, motivating the exploration of complementary immunotherapies. Accordingly, cancer vaccines offer an attra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleisner, María Alejandra, Pereda, Cristián, Tittarelli, Andrés, Navarrete, Mariela, Fuentes, Camila, Ávalos, Ignacio, Tempio, Fabian, Araya, Juan Pablo, Becker, María Inés, González, Fermín Eduardo, López, Mercedes Natalia, Salazar-Onfray, Flavio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373330/ https://www.ncbi.nlm.nih.gov/pubmed/32690772 http://dx.doi.org/10.1136/jitc-2020-000999

Ejemplares similares

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
por: Hamdan, Firas, et al.
Publicado: (2021)

Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
por: Munoz, Luis Enrique, et al.
Publicado: (2021)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
por: Ponce, Santiago, et al.
Publicado: (2023)

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
por: Alvarez, Maite, et al.
Publicado: (2021)

Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
por: Rodriguez-Ruiz, Maria E, et al.
Publicado: (2023)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis
por: Wang, Duo, et al.
Publicado: (2023)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
por: Moreno, Victor, et al.
Publicado: (2021)

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma
por: Beasley, Georgia M, et al.
Publicado: (2022)

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
por: Muñoz, Nina M., et al.
Publicado: (2021)

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
por: Morales-Molina, Alvaro, et al.
Publicado: (2021)

Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment
por: Guo, Fengguang, et al.
Publicado: (2022)

Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts
por: Veitch, Margaret, et al.
Publicado: (2023)

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
por: Yu, Xiaolu, et al.
Publicado: (2022)

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
por: Garcia-Carbonero, Rocio, et al.
Publicado: (2022)

Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
por: Su, Yinghan, et al.
Publicado: (2022)

Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination
por: Carlson, Peter M, et al.
Publicado: (2023)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry
por: Nguyen, Teresa T, et al.
Publicado: (2022)

Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors
por: Hoover, Ashley R, et al.
Publicado: (2022)

PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8(+) T cell-dependent antitumor immunity and abscopal effect after local irradiation
por: Yoon, Yi Na, et al.
Publicado: (2022)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
por: Bhatta, Maulasri, et al.
Publicado: (2021)

Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors
por: Reil, Katherine A, et al.
Publicado: (2023)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models
por: Lopes, Alessandra, et al.
Publicado: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Taki, Shunichi, et al.
Publicado: (2021)

OncoVEX(mGM-CSF)expands tumor antigen-specific CD8+ T-cell response in preclinical models
por: Estrada, Juan, et al.
Publicado: (2023)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
por: Anfray, Clément, et al.
Publicado: (2021)

Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
por: Alshebremi, Mohammad, et al.
Publicado: (2023)

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
por: Khalique, Hena, et al.
Publicado: (2021)

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
por: Ghonime, Mohammed G, et al.
Publicado: (2021)

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
por: Nelson, Adam, et al.
Publicado: (2022)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8(+) T cell immunity to reject ‘cold’ tumors
por: Semmrich, Monika, et al.
Publicado: (2022)

Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
por: Zhang, Bo, et al.
Publicado: (2021)

Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
por: Shakfa, Noor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ioe2e2cntj56u1did3ptslajkl